
Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta-Analysis
2013; Wiley; Volume: 94; Issue: 3 Linguagem: Inglês
10.1038/clpt.2013.99
ISSN1532-6535
AutoresLuciane Cruz Lopes, F.A. Spencer, I Neumann, Matthew Ventresca, Shanil Ebrahim, Qi Zhou, Neera Bhatnaga, Sam Schulman, John W. Eikelboom, Gordon Guyatt,
Tópico(s)Vitamin K Research Studies
ResumoClinical Pharmacology & TherapeuticsVolume 94, Issue 3 p. 367-375 Review Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta-Analysis L C Lopes, Corresponding Author L C Lopes [email protected] Pharmaceutical Sciences Postgraduate Course, University of Sorocaba, UNISO, Sorocaba, BrazilSearch for more papers by this authorF A Spencer, F A Spencer Division of Hematology/Thrombosis, Department of Medicine, McMaster University, Hamilton, Ontario, Canada Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorI Neumann, I Neumann Department of Internal Medicine, Pontificia Universidad Catolica de Chile, Santiago, ChileSearch for more papers by this authorM Ventresca, M Ventresca Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorS Ebrahim, S Ebrahim Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorQ Zhou, Q Zhou Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorN Bhatnaga, N Bhatnaga Health Sciences Library, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorS Schulman, S Schulman Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada Department of Medicine, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorJ Eikelboom, J Eikelboom Division of Hematology/Thrombosis, Department of Medicine, McMaster University, Hamilton, Ontario, Canada Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorG Guyatt, G Guyatt Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this author L C Lopes, Corresponding Author L C Lopes [email protected] Pharmaceutical Sciences Postgraduate Course, University of Sorocaba, UNISO, Sorocaba, BrazilSearch for more papers by this authorF A Spencer, F A Spencer Division of Hematology/Thrombosis, Department of Medicine, McMaster University, Hamilton, Ontario, Canada Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorI Neumann, I Neumann Department of Internal Medicine, Pontificia Universidad Catolica de Chile, Santiago, ChileSearch for more papers by this authorM Ventresca, M Ventresca Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorS Ebrahim, S Ebrahim Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorQ Zhou, Q Zhou Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorN Bhatnaga, N Bhatnaga Health Sciences Library, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorS Schulman, S Schulman Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada Department of Medicine, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorJ Eikelboom, J Eikelboom Division of Hematology/Thrombosis, Department of Medicine, McMaster University, Hamilton, Ontario, Canada Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this authorG Guyatt, G Guyatt Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, CanadaSearch for more papers by this author First published: 13 May 2013 https://doi.org/10.1038/clpt.2013.99Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Vitamin K antagonists (VKAs) prevent stroke in atrial fibrillation (AF) at the cost of bleeding risk. To determine major bleeding rates in AF patients, we conducted a systematic review that identified 51 eligible studies including more than 342,699 patients. The pooled estimate of the rate of major bleeding was 2.51 (99% confidence interval: 2.03–3.11) bleeds per 100 patient-years. The results represent the best estimates of bleeding risk that most patients contemplating VKA use may expect. Clinical Pharmacology & Therapeutics (2013); 94 3, 367–375. doi:10.1038/clpt.2013.99 Citing Literature Supporting Information Filename Description cptclpt201399-sup-0001.docapplication/doc, 111 KB Supplementary Table S1 cptclpt201399-sup-0002.docapplication/doc, 437 KB Supplementary Table S2 cptclpt201399-sup-0003.docapplication/doc, 527 KB Supplementary Table S3 cptclpt201399-sup-0004.docapplication/doc, 45 KB Supplementary Data Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume94, Issue3Reinventing BioinnovationSeptember 2013Pages 367-375 RelatedInformation
Referência(s)